Literature Analysis: Novel Splicing Variants of ErbB2 Mediate Drug Resistance in Tumors

Article Information

Journal: Frontiers in Oncology

Research Focus: Full‑length transcriptome sequencing, ErbB2 splicing variants, tumor drug resistance, antibody targeting

Key Molecule: ErbB2 i14e splice variant

Core Finding: A novel exon‑insertion splice variant of ErbB2 induces resistance to anti‑ErbB2 monoclonal antibodies

Research Background

ErbB2 (HER2) is a receptor tyrosine kinase of the EGFR family that governs cell proliferation, survival, migration, and differentiation. Its overexpression or gene amplification drives the progression of numerous solid tumors, including breast cancer, gastric cancer, and gallbladder cancer. Anti‑ErbB2 monoclonal antibodies have revolution clinical outcomes, but primary and acquired drug resistance remains a major obstacle to effective treatment.

Traditional studies have focused on genetic mutations or pathway compensation as resistance mechanisms, while transcript‑level structural variations and their roles in antibody recognition have long been overlooked.

Research Approach

1. Full‑length transcriptome sequencing was used to systematically profile transcript isoforms in gallbladder cancer.
2. Novel ErbB2 splice variants were identified and validated.
3. Functional experiments were performed to evaluate receptor dimerization, downstream signaling, and cell behavior.
4. Structural simulation and competitive binding assays were used to analyze antibody‑variant interactions.
5. Clinical correlation was established between variant expression and patient prognosis.

Research Outcomes

1. A previously unknown ErbB2 splice variant, ErbB2 i14e, was discovered. It contains a 102‑bp exon insertion in intron 14, encoding an extra 34 amino acids in the extracellular IV domain.
2. This variant is expressed in 25.5% of gallbladder cancer specimens and is significantly associated with poor prognosis.
3. The inserted peptide enhances heterodimerization with ErbB3 and stabilizes the complex, leading to sustained activation of the PI3K/AKT pathway.
4. The extra peptide creates steric hindrance that blocks therapeutic antibodies from binding to their epitope, thereby mediating resistance to anti‑ErbB2 therapies.
5. This represents a novel resistance mechanism independent of gene mutation or canonical pathway activation.

Image Location

[Image: Schematic diagram of ErbB2 i14e variant formation, antibody binding blockage, and downstream signaling activation]

Product Empowerment by ANT BIO PTE. LTD.

This research relies on high‑quality reagents to achieve accurate detection and functional validation. ANT BIO PTE. LTD. provides a full suite of validated tools to support similar studies:

• Variant‑Specific Antibodies: Enable precise identification of wild‑type and splice variant forms of ErbB2.
• Phospho‑Specific Antibodies: Quantify activation levels of PI3K, AKT, and downstream signaling molecules.
• ELISA Kits: Support quantitative analysis of soluble receptors and drug binding efficiency.
• General Reagents: Ensure stability and reproducibility in cell culture, protein extraction, and Western blotting.

These reagents enable researchers to:

• Detect variant expression with high specificity
• Analyze signaling pathway activation
• Evaluate antibody binding affinity
• Validate clinical sample correlations

Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering global life science researchers with high‑quality, reliable, and standardized reagents. We integrate innovative tools across basic research, translational medicine, and clinical validation to accelerate breakthroughs in tumor biology, drug resistance, and precision therapy.

Related Product List

Brand Promotion

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.